Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Brian Abbott, MD

Brian Abbott, MD, Medical Director of Hematology, Big Sky OncologyMedical Director of Hematology
Big Sky Oncology
Member of the Healthcare Council

Brian Abbott, MD, is the Medical Director of Hematology at Big Sky Oncology and Sletten Cancer Institute in Great Falls, Montana. His specialties include acute and chronic leukemias (AML, ALL, CML, CLL), all forms of lymphomas including Non-Hodgkin’s and Hodgkin's Lymphoma, myelomas, bone and marrow transplants (BMT), myelodysplastic syndrome (MDS), and aplastic anemia. Dr. Abbott also treats significant numbers of lung, colon, and breast cancer patients. He has interest in venture capital and hedge fund due diligence, and investment analysis in early stage pharmaceutical companies. He has experience in consulting with venture capital firms regarding biotechnology start-up investment opportunities. He has a special interest in consulting with pharmaceutical companies regarding acquisitions and in design of clinical trials, and providing the insight of a physician who has worked in academic and community oncology practice environments. (This is me - Update Profile)


Employment History
2007 - present Medical Director of Hematology
Big Sky Oncology
2007 - present Medical Director, Hematology Division
Sletten Cancer Institute
2005 - 2006 Assistant Professor of Medicine
University of Colorado Health Sciences Center

GLG NewsSM Analyses by Brian Abbott, MD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
TREANDA for CLL could be a winner | 05-19-2008
Author: Brian Abbott, MD, Medical Director of Hematology, Big Sky Oncology

The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.

National healthcare? Better find a new pool of physicians | 05-19-2008
Author: Brian Abbott, MD, Medical Director of Hematology, Big Sky Oncology

National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?

Medicare: heading toward a crisis | 05-19-2008
Analysis of: Loss of Doctors Leaves Patients Waiting | www.redorbit.com
Author: Brian Abbott, MD, Medical Director of Hematology, Big Sky Oncology

The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.

The Vidaza survival benefit news is a positive for MGI Pharma's Dacogen | 11-19-2007
Analysis of: Vidaza vs Dacgoen for MDS | www.newratings.com
Author: Brian Abbott, MD, Medical Director of Hematology, Big Sky Oncology

There is no reason to believe Dacogen is inferior to Vidaza. In some studies, Dacogen seems to produce a deeper quality of response, and may also prove more beneficial in AML.

GLG InstituteSM Seminars with Brian Abbott, MD(?)

 
Brian Abbott, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Brian Abbott, MD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-09-07T01:45:17.680